+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

NETRF Investigator Award

Neuroendocrine Tumor Research Foundation

Purpose

Investigator Awards provide $300,000 over two years ($150,000/year). Proposals typically include two aims (or three smaller aims) that describe work to be completed within the two-year award period. Projects are usually led by a single principal investigator (PI), with or without collaborators. These awards are comparable in scope to an NIH R21 grant.

Amount

This grant award totals $300,000 over two years. Up to 10% in indirect costs may be requested. Indirect costs are included in the total budget. Grants will be paid in US dollars.

Conditions

Projects that bring together investigators from diverse scientific disciplines are highly encouraged. For team applications, one principal investigator and one institution must be selected. International applications are welcome.
Awardees, as a condition of acceptance, will be required to attend the annual NETRF Research Symposium. Funds from the awarded grant should be allocated to attend the Annual NETRF Symposium.

Selection process

The NETRF request for applications uses a two-step process. First, applicants submit a competitive Letter of Intent (LOI). Only one LOI may be submitted per applicant, per program. Applicants selected to advance will be invited to submit a full application.

An LOI must be submitted, and all eligibility criteria must be met to be considered for the full application stage. LOIs that do not meet these requirements will be administratively rejected.
If invited, applicants must submit a full application that meets all program guidelines. Applications that do not meet these requirements will be administratively rejected.
LOIs and full applications will be peer reviewed by an independent panel of scientific experts.

Grant monitoring

Grant recipients are required to submit progress reports every six months detailing scientific progress, research milestones achieved, and project-related expenditures. The reports disclose updates on publications, patents and clinical trial advances when applicable. These reports are reviewed to ensure funds are spent appropriately and that sufficient progress is made throughout the grant term. Continued funding is contingent upon review and approval of progress and achievement of relevant milestones. Post-award reports at one, three and five years are required to measure longer-term outcomes of the funded research.

Applicants interested in a 2026 award must submit a competitive letter of intent (LOI) by 5:00 PM ET on Monday, March 16, 2026.
By early May 2026, a limited number of LOI Applicants will be invited to submit full proposals. Full proposals are due Monday, June 22, 2026, by 5:00 PM ET.

AI Based Application Success Predictor

🧠 1. Strict Focus on Neuroendocrine Tumors (Non-Negotiable)

Projects must directly address:
- Neuroendocrine tumors (NETs) or neuroendocrine carcinomas (NECs)
Includes:
- Pancreatic NETs
- Carcinoid tumors

👉 Non-NET oncology → not competitive

🎯 2. Alignment with NETRF Research Pillars (Top Predictor)

NETRF funding is structured around three core pillars:

Early Detection (biomarkers, imaging, risk prediction)
New Therapeutics (targeted therapy, immunotherapy)
Precision Medicine (personalized treatment approaches)

👉 Proposals must clearly align with at least one pillar

🔄 3. Strong Translational Pathway (Critical)

NETRF supports:
- Basic + translational + clinical research
But expects:
- Clear progression toward:
  - Diagnosis
  - Treatment
  - Patient benefit

👉 Key question:
“How will this advance NET diagnosis or treatment?”

🚀 4. Innovation & Breakthrough Potential

NETRF prioritizes:
- Highly innovative research
Funded work often includes:
- Novel therapies
- New biological insights

👉 Incremental research is less competitive

🧬 5. Biomarkers, Imaging & Precision Oncology (High Priority Areas)

High success areas include:

Molecular biomarkers
Functional imaging
Tumor profiling

👉 These directly support:

Early detection + precision medicine pillars

💊 6. Focus on Therapeutic Development & Resistance

Strong interest in:
- New targeted therapies
- Immunotherapy
- Overcoming treatment resistance

👉 Especially important for advanced/metastatic NETs

🧪 7. Feasible, Milestone-Driven Research Plan

Funding ranges:
- ~$100K to $800K depending on grant type
Requires:
- Clear milestones
- Progress reporting

👉 Continued funding depends on measurable progress

👩‍🔬 8. Investigator Strength & Career Stage Fit

Supports:
- Early-career (Mentored/Pilot awards)
- Established investigators (Investigator/Accelerator awards)

👉 Matching the correct grant mechanism is crucial

🤝 9. Collaborative & Multidisciplinary Research (Advantage)

NETRF promotes:
- Collaboration across:
  - Oncology
  - Molecular biology
  - Imaging

👉 Complex, team-based proposals perform better

📈 10. Potential for Clinical Impact & Future Funding

NETRF funding acts as:
- Catalyst for larger grants and clinical trials
Strong proposals:
- Lead to:
  - Publications
  - Clinical translation

👉 Long-term impact is a key evaluation factor

📊 Summary: Key Predictors (Ranked)

Highest impact factors:

NET-specific focus
Alignment with NETRF pillars
Translational pathway

Moderate predictors:
4. Innovation
5. Biomarkers / precision medicine
6. Therapeutic relevance

Supporting factors:
7. Feasibility
8. Investigator strength
9. Collaboration

💡 Insider Insight

Compared to general cancer funders:

Neuroendocrine Tumor Research Foundation is:
👉 highly niche (NET-only)
👉 strategically structured around detection → treatment → personalization

👉 Winning formula:
NET-focused idea + aligned with pillars + clear translational impact

✔️ What wins:

Biomarker-driven early detection
Precision medicine approaches
Novel therapies targeting NET biology

❌ What struggles:

Non-NET oncology
Pure basic science without application
Weak alignment with NETRF roadmap

Specialties

Endocrine Surgery

Neurosciences

Eligibility Requirements

The Neuroendocrine Tumor Research Foundation (NETRF) seeks investigators and teams with the tools to study neuroendocrine cancers in innovative and transformative ways.

Applicants must have an MD, PhD, MD/PhD, or equivalent degree and be appointed as faculty at the Assistant Professor level or above (or equivalent position). Research track faculty are eligible to apply.
Applicants must have the skills, knowledge, and resources necessary to carry out the proposed research.
Eligible organizations include public or private institutions, such as universities, colleges, hospitals, and laboratories, both in and outside of the United States. Applications from the biotech, pharmaceutical, or for-profit life sciences industries are not eligible.

Sponsor Details

Sponsor Institute/Organizations: Neuroendocrine Tumor Research Foundation

Sponsor Type: Corporate/Non-Profit

Address: 100 Hancock Street, Third Floor, Quincy, MA 02171 (617) 946-1780

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity